142 related articles for article (PubMed ID: 38666761)
1. Immunohistochemistry of Lung Cancer Biomarkers.
Beasley MB
Adv Anat Pathol; 2024 Apr; ():. PubMed ID: 38666761
[TBL] [Abstract][Full Text] [Related]
2. Anaplastic lymphoma kinase 5A4 immunohistochemistry as a diagnostic assay in lung cancer: A Canadian reference testing center's results in population-based reflex testing.
Fiset PO; Labbé C; Young K; Craddock KJ; Smith AC; Tanguay J; Pintilie M; Wang R; Torlakovic E; Cheung C; da Cunha Santos G; Ko HM; Boerner SL; Hwang DM; Leighl NB; Tsao MS
Cancer; 2019 Nov; 125(22):4043-4051. PubMed ID: 31390053
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemistry for predictive biomarkers in non-small cell lung cancer.
Mino-Kenudson M
Transl Lung Cancer Res; 2017 Oct; 6(5):570-587. PubMed ID: 29114473
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic value of a novel fully automated immunochemistry assay for detection of ALK rearrangement in primary lung adenocarcinoma.
Ying J; Guo L; Qiu T; Shan L; Ling Y; Liu X; Lu N
Ann Oncol; 2013 Oct; 24(10):2589-2593. PubMed ID: 23904459
[TBL] [Abstract][Full Text] [Related]
5. FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1.
Sul J; Blumenthal GM; Jiang X; He K; Keegan P; Pazdur R
Oncologist; 2016 May; 21(5):643-50. PubMed ID: 27026676
[TBL] [Abstract][Full Text] [Related]
6. Discordance between Immunohistochemistry and Erb-B2 Receptor Tyrosine Kinase 2 mRNA to Determine Human Epidermal Growth Factor Receptor 2 Low Status for Breast Cancer.
Xu K; Bayani J; Mallon E; Pond GR; Piper T; Hasenburg A; Markopoulos CJ; Dirix L; Seynaeve CM; van de Velde CJH; Rea DW; Bartlett JMS
J Mol Diagn; 2022 Jul; 24(7):775-783. PubMed ID: 35526835
[TBL] [Abstract][Full Text] [Related]
7. ALK Protein Analysis by IHC Staining after Recent Regulatory Changes: A Comparison of Two Widely Used Approaches, Revision of the Literature, and a New Testing Algorithm.
Marchetti A; Di Lorito A; Pace MV; Iezzi M; Felicioni L; D'Antuono T; Filice G; Guetti L; Mucilli F; Buttitta F
J Thorac Oncol; 2016 Apr; 11(4):487-95. PubMed ID: 26916631
[TBL] [Abstract][Full Text] [Related]
8. Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib.
Yang CY; Liao WY; Ho CC; Chen KY; Tsai TH; Hsu CL; Liu YN; Su KY; Chang YL; Wu CT; Liao BC; Hsu CC; Hsu WH; Lee JH; Lin CC; Shih JY; Yang JC; Yu CJ
Oncologist; 2020 Aug; 25(8):702-711. PubMed ID: 32386255
[TBL] [Abstract][Full Text] [Related]
9. Concordance of Immunohistochemistry and Fluorescence In Situ Hybridization in the Detection of Anaplastic Lymphoma Kinase (ALK) and Ros Proto-oncogene 1 (ROS1) Gene Rearrangements in Non-Small Cell Lung Carcinoma: A 4.5-Year Experience Highlighting Challenges and Pitfalls.
Nambirajan A; Sood R; Khatoon W; Malik PS; Mohan A; Jain D
Arch Pathol Lab Med; 2023 Dec; ():. PubMed ID: 38054562
[TBL] [Abstract][Full Text] [Related]
10. A comparative analysis of immunohistochemistry and fluorescent
Wagle PB; Jambhekar NA; Kumar R; Prabhash K; Pramesh CS; Desai SB; Noronha V; Karimundackal G; Shah A; Joshi A; Laskar SG; Jiwnani S; Pai T; Agarwal JP
Indian J Cancer; 2017; 54(1):148-154. PubMed ID: 29199679
[TBL] [Abstract][Full Text] [Related]
11. Responses to crizotinib in patients with ALK-positive lung adenocarcinoma who tested immunohistochemistry (IHC)-positive and fluorescence in situ hybridization (FISH)-negative.
Ma D; Wang Z; Yang L; Mu X; Wang Y; Zhao X; Li J; Lin D
Oncotarget; 2016 Sep; 7(39):64410-64420. PubMed ID: 27418132
[TBL] [Abstract][Full Text] [Related]
12. Detection of novel and potentially actionable anaplastic lymphoma kinase (ALK) rearrangement in colorectal adenocarcinoma by immunohistochemistry screening.
Lee J; Kim HC; Hong JY; Wang K; Kim SY; Jang J; Kim ST; Park JO; Lim HY; Kang WK; Park YS; Lee J; Lee WY; Park YA; Huh JW; Yun SH; Do IG; Kim SH; Balasubramanian S; Stephens PJ; Ross JS; Li GG; Hornby Z; Ali SM; Miller VA; Kim KM; Ou SH
Oncotarget; 2015 Sep; 6(27):24320-32. PubMed ID: 26172300
[TBL] [Abstract][Full Text] [Related]
13. [Challenges of immunohistochemistry for individualized cancer chemotherapy].
Kamoshida S
Rinsho Byori; 2014 Jul; 62(7):710-8. PubMed ID: 25669042
[TBL] [Abstract][Full Text] [Related]
14. Somatic mutations and immune checkpoint biomarkers.
Parris BA; Shaw E; Pang B; Soong R; Fong K; Soo RA
Respirology; 2019 Mar; 24(3):215-226. PubMed ID: 30636374
[TBL] [Abstract][Full Text] [Related]
15. Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation.
Paver EC; Cooper WA; Colebatch AJ; Ferguson PM; Hill SK; Lum T; Shin JS; O'Toole S; Anderson L; Scolyer RA; Gupta R
Pathology; 2021 Feb; 53(2):141-156. PubMed ID: 33388161
[TBL] [Abstract][Full Text] [Related]
16. Screening for ROS1 gene rearrangements in non-small-cell lung cancers using immunohistochemistry with FISH confirmation is an effective method to identify this rare target.
Selinger CI; Li BT; Pavlakis N; Links M; Gill AJ; Lee A; Clarke S; Tran TN; Lum T; Yip PY; Horvath L; Yu B; Kohonen-Corish MR; O'Toole SA; Cooper WA
Histopathology; 2017 Feb; 70(3):402-411. PubMed ID: 27599111
[TBL] [Abstract][Full Text] [Related]
17. Challenges and future of biomarker tests in the era of precision oncology: Can we rely on immunohistochemistry (IHC) or fluorescence
Chae YK; Arya A; Chiec L; Shah H; Rosenberg A; Patel S; Raparia K; Choi J; Wainwright DA; Villaflor V; Cristofanilli M; Giles F
Oncotarget; 2017 Nov; 8(59):100863-100898. PubMed ID: 29246028
[TBL] [Abstract][Full Text] [Related]
18. Impact of Decalcification, Cold Ischemia, and Deglycosylation on Performance of Programmed Cell Death Ligand-1 Antibodies With Different Binding Epitopes: Comparison of 7 Clones.
Lawson NL; Scorer PW; Williams GH; Vandenberghe ME; Ratcliffe MJ; Barker C
Mod Pathol; 2023 Sep; 36(9):100220. PubMed ID: 37230414
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic Utility of PD-L1 Expression in Lung Adenocarcinoma: Immunohistochemistry and RNA In Situ Hybridization.
Gafeer MM; Hosny Mohammed K; Ormenisan-Gherasim C; Choudhary F; Siddiqui MT; Cohen C
Appl Immunohistochem Mol Morphol; 2018 Sep; 26(8):e86-e90. PubMed ID: 28968265
[TBL] [Abstract][Full Text] [Related]
20. On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomas.
Mescam-Mancini L; Lantuéjoul S; Moro-Sibilot D; Rouquette I; Souquet PJ; Audigier-Valette C; Sabourin JC; Decroisette C; Sakhri L; Brambilla E; McLeer-Florin A
Lung Cancer; 2014 Feb; 83(2):168-73. PubMed ID: 24380695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]